Search for Companies, Tipsters or Sources…
Companies
Tipsters
Brokers
Sources
Or view the latest share tips
Company Results
Tipster results
Broker results
Sources results
Fund Manager results
Tips from these results
Recent Share tips:
- Watch Oxford Nanopore Technologies (ONT) by Ben McPoland in The Motley Fool
- Avoid Tribal Group (TRB) by Steve Moore in ShareProphets
- Add Pensana (PRE) by Mark Tovey in The Motley Fool
- Buy Ibstock (IBST) by Stephen Wright in The Motley Fool
- Buy Games Workshop Group (GAW) by Ben McPoland in The Motley Fool
- Buy Volution Group (FAN) by Ben McPoland in The Motley Fool
- Neutral Deliveroo Class A (ROO) by Citi
- Outperform Sainsbury (J) (SBRY) by Exane
- Buy Haleon (HLN) by Societe Generale
- Neutral Coca-Cola Europacific Partners (DI) (CCEP) by ODDO BHF
- Watch HSBC Holdings (HSBA) by John Fieldsend in The Motley Fool
- Neutral Kingfisher (KGF) by Credit Suisse
- Buy Trustpilot Group (TRST) by Berenberg
- Buy Vodafone Group (VOD) by Deutsche Bank
- Sell InterContinental Hotels Group (IHG) by Redburn
- Hold Centamin (DI) (CEY) by Russ Mould in The Telegraph - Questor
- Outperform Centrica (CNA) by Credit Suisse
- Sector Perform Empiric Student Property (ESP) by RBC Capital
- Hold Intertek Group (ITRK) by Jefferies
- Outperform Rentokil Initial (RTO) by RBC Capital
Oxford Biomedica (OXB)
Health Care Sector
Members only
To view this content and much more please Sign Up
NOTE: This is based on 116 open tips for this company
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
| Trading Velocity : Premium Only | Activity Score : Premium Only |
| Consensus Score : Premium Only | Momentum Score : Premium Only |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Kevin Godbold | – | 2023-03-08 13:05:00 08/03/2023 | – |
| – | RBC Capital | – | 2022-10-11 05:47:00 11/10/2022 | – |
| – | RBC Capital | – | 2022-07-01 07:13:00 01/07/2022 | – |
| – | RBC Capital | – | 2022-06-30 18:00:00 30/06/2022 | – |
| – | RBC Capital | – | 2022-06-21 18:00:00 21/06/2022 | – |
| Latest Bid : – | Latest Ask : – |
| High Today : – | Low Today : – |
| This Years High : – | This Years Low : – |
| Volume : – | MKT Cap : – |
Oxford Biomedica Overview
Oxford Biomedica develops innovative new IP-protected , LentiVector® based therapies, leveraging our internal research expertise and know-how. We select patient-centric product candidates and progress these through proof-of-concept, and into early clinical development, before either seeking third-party funding for full development and commercialisation or to develop further in-house.Latest Oxford Biomedica Tips
| Type | Tipster | SectorScore | Start date | Performance |
|---|---|---|---|---|
| – | Kevin Godbold | – | 2023-03-08 13:05:00 08/03/2023 | – |
| – | RBC Capital | – | 2022-10-11 05:47:00 11/10/2022 | – |
| – | RBC Capital | – | 2022-07-01 07:13:00 01/07/2022 | – |
| – | RBC Capital | – | 2022-06-30 18:00:00 30/06/2022 | – |
| – | RBC Capital | – | 2022-06-21 18:00:00 21/06/2022 | – |
Stock Splits and Consolidations
30/05/2018 – Stock Consolidation 50.000:1.000